ClinicalTrials.gg
CompletedNCT06393972Updated Oct 26, 2026

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

A Phase 2 interventional study of Tofacitinib 5 MG BID in Glucocorticoid Resistant ICIs-related Myocarditis, sponsored by Shanghai Zhongshan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now CompletedFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myocarditis with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Myocarditis · China.

Started
2024
with 1 other
Phase 2
Only one
of the 14
Registered
8th of 14
by date
Lead sponsor
1 of 14
Shanghai Zhongshan Hospital

Among the 14 studies in Myocarditis with a site in China, this one is one of 2 that started in 2024, is the only one in phase 2, and was the 8th registered.

Myocarditis

175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

Browse Myocarditis studies →

Open to participants now

10 of the 14 studies in Myocarditis with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myocarditis with a site in China, or all of them as a file.
02

Study summary

The efficacy and safety of Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a single-arm, prospective, phase 2 trial

03

Conditions studied

  • Glucocorticoid Resistant ICIs-related Myocarditis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. Patients treated with ICI immunotherapy (monotherapy or combination), including anti-PD1, anti-PDL1, anti-CTLA4; and including any type of cancer (even those in which ICI is not currently approved by regulatory)
  3. Definite, probable or possible ICI-induced myocarditis according to the diagnostic criteria of the most recent expert consensus recommendations (e.g27, to be updated with any new recommendations to be published)
  4. -resistant ICI-myocarditis: Corticosteroid-resistant ICI-myocarditis is defined by the absence of decrease in troponin levels or the appearance/persistence of severity criteria despite receiving prednisone dose ≥0.5 mg/kg/day for ≥2 days.
  5. Signature of before any trial procedure from the patient or legal representative or the close relative
  6. Patients covered by social security regimen (excepting AME)
  7. Withhold of ICI

Exclusion criteria

Exclusion Criteria:

  1. Untreated and/or uncontrolled bacterial, fungal, or viral infection Pregnancy, breast-feeding or planning to become pregnant during the study period
  2. For women of childbearing age, lack of effective throughout the duration of participation in the study
  3. Being treated with tofacitinib within 3 months prior to inclusion Known to abatacept or belatacept
  4. Being treated with anti-thymoglobulin, or alemtuzumab within 6 weeks of the first scheduled dose of abatacept
  5. Patient participating to another interventional study (RIPH 1 only) People under legal protection measure (tutorship, curatorship or safeguard measures)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Tofacitinib

    Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis

    Drug: Tofacitinib 5 MG BID

Interventions

06

What researchers measure

Primary outcomes

  1. All-cause mortality within three months

    All-cause mortality within three months

    Time frame: The first three months after tofacitinib administration

Secondary outcomes

  1. All-cause mortality within six months

    All-cause mortality within six months

    Time frame: The firs six months after tofacitinib administration

  2. Progression-free survival

    Progression-free survival

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

  3. Overall survival

    Overall survival

    Time frame: From date of enrollment until the date of death from any cause, assessed up to 24 months"

  4. Safety and tolerability based on incidence of treatment-emergent adverse events

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200032, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2024 to primary completion in Jul 2025, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jul 2024 → Apr 2024, primary completion Nov 2025 → Jul 2025 and completion Nov 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
May 1, 2024
StartActual
Apr 10, 2024was Jul 2024
Primary completionActual
Jul 11, 2025was Nov 2025
CompletionActual
Dec 16, 2025was Nov 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 26, 2026
Sites
1 site added — first site in China
Show site
  • Zhongshan Hospital, Fudan University · Shanghai, China
Oct 26, 2026
Start date
Jul 1, 2024→Apr 10, 2024 (actual)
Oct 26, 2026
Primary completion
Nov 30, 2025→Jul 11, 2025 (actual)
Oct 26, 2026
Study completion
Nov 30, 2026→Dec 16, 2025 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Completed
    1 site added — first site in China
    Show site
    • Zhongshan Hospital, Fudan University · Shanghai, China
    Start date Jul 1, 2024→Apr 10, 2024 (now actual)
    Primary completion Nov 30, 2025→Jul 11, 2025 (now actual)
    Study completion Nov 30, 2026→Dec 16, 2025 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06393972
Responsible party
Tianshu Liu (Clinical Professor, Shanghai Zhongshan Hospital) — Principal investigator
First posted
May 1, 2024
Start date
Apr 10, 2024
Primary completion
Jul 11, 2025
Completion
Dec 16, 2025
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion